Soglizin LX-4211 is a new oral diabetes drug developed by Sanofi and Lescon Pharmaceuticals. As a dual inhibitor of SGLT-1 and SGLT-2, the drug can reduce postprandial blood glucose, increase GLP-1 and promote urinary glucose excretion.
